Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that finasteride-induced DHT deficiency intensified constitutive iNOS expression in rat testicular and epididymal cells, suggesting a complex regulatory relationship needing further investigation.

This study indicates that the normal human prostate is not a major contributor to circulating blood DHT concentrations in androgen-deficient patients receiving testosterone replacement therapy.

This study found that rat male costochondral chondrocytes, unlike female chondrocytes, respond to testosterone through metabolism to dihydrotestosterone, which shows a maturation-state dependent effect in male growth plate cells.

This study reported that prenatal exposure to dihydrotestosterone altered long-term androgen metabolism in juvenile male rats, suggesting different regulatory mechanisms for 5a-reductase in hypothalamic versus pituitary tissues.

This study found that finasteride altered androgen receptor expression in the rat epididymis without affecting the morphology of epididymal epithelium, suggesting a change in hormonal status.

This study suggests that dihydrotestosterone plays a key role in the development of chronic allograft nephropathy, and inhibiting androgens may improve long-term kidney transplant outcomes.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.

In this study, DHT was observed to have varying effects on hair follicle growth and related protein expression depending on concentration, with the Wnt/β-catenin pathway potentially playing a significant role.

This study found that ginsenoside F2 may suppress hair cell apoptosis and improve hair growth outcomes in a DHT-induced hair loss model more effectively than finasteride.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

In this study, high concentrations of dihydrotestosterone and testosterone reduced the growth of human hair follicle cells in vitro, while high estradiol levels increased their growth.

This study found that dihydrotestosterone (DHT) may shorten the hair growth cycle through mechanisms like cell-cycle arrest and β-catenin downregulation in rat hair follicle cells.

This study observed that electro-acupuncture reduced global DNA methylation and DNMT3b expression in a PCOS-like rat model, suggesting a role of hypothalamic DNA methylation in PCOS development and treatment.

This study found that dihydrotestosterone (DHT) regulates the degradation of p27 in MCF-7 breast cancer and OVCAR-3 ovarian cancer cells, involving SKP2 as a key factor.

In this study, 17β-estradiol increased VEGF production in differentiated THP-1 cells, while dihydrotestosterone counteracted this effect by modulating adenylate cyclase activity.

This study found that young women with female-pattern hair loss exhibit increased testosterone production rates while dihydrotestosterone production rates remain within or below the normal range.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

This study found that a commonly-used DHT enzyme immunoassay shows significant cross-reactivity with testosterone, leading to inaccurate DHT measurements compared to a gold-standard LC–MS/MS method.

This study found that L-ascorbic acid 2-phosphate could reduce DHT-induced DKK-1 expression in balding scalp cells, suggesting potential for treating androgen-driven hair loss.

This study identified several genes regulated by dihydrotestosterone in an SV40T-transformed human dermal papilla cell line, which may play a role in androgen-mediated hair growth regulation.

This study found that sulforaphane treatment enhanced hair regeneration in ob/ob mice by increasing DHT-degrading enzyme levels and lowering plasma testosterone and DHT.

Topical finasteride doesn't reduce DHT levels, hinting at an endocrine role in hair loss.

This study found that testosterone may promote glioblastoma progression by being converted into dihydrotestosterone, which enhances cell proliferation, migration, and invasion in GBM cell lines.

Finasteride increases hair growth, prolongs hair cycle, and lowers dihydrotestosterone levels.

Finasteride significantly reduces DHT levels in male dogs without affecting testosterone levels, suggesting it could be used to treat benign prostatic hypertrophy in dogs weighing 10 to 50 kilograms.

This study isolated a bioactive peptide from Trapa japonica fruit and found that it may protect human dermal papilla cells from DHT-induced stress, suggesting potential for biomedical applications.

This study found that the total testosterone/dihydrotestosterone ratio correlates with a negative metabolic profile in both women with PCOS and healthy women.

This abstract suggests that finasteride's suppression of DHT may link DHT to migraine causes, or it may benefit migraines by other finasteride properties like testosterone modulation, but reports no new empirical findings.

Testosterone, DHT, and estradiol significantly affect hair cell growth.